NASDAQ:TXMD TherapeuticsMD (TXMD) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free TXMD Stock Alerts $1.88 +0.01 (+0.53%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.86▼$1.9050-Day Range$1.86▼$2.6952-Week Range$1.86▼$4.73Volume6,212 shsAverage Volume20,942 shsMarket Capitalization$21.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get TherapeuticsMD alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About TherapeuticsMD Stock (NASDAQ:TXMD)TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Read More TXMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TXMD Stock News HeadlinesApril 25, 2024 | americanbankingnews.comTherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.comApril 19, 2024 | americanbankingnews.comTherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.comApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. March 29, 2024 | businesswire.comTherapeuticsMD Announces Full Year 2023 Financial ResultsMarch 12, 2024 | msn.com25 Countries With Highest Abortion RatesMarch 10, 2024 | sg.finance.yahoo.comTherapeuticsMD, Inc. (TXMD) stock historical prices & data – Yahoo FinanceDecember 29, 2023 | morningstar.comTherapeuticsMD Inc TXMDNovember 15, 2023 | nasdaq.comDaily Markets: Today Brings Producer Prices, Retail Sales DataApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. November 14, 2023 | marketwatch.comTherapeuticsMD to Consider Strategic AlternativesNovember 14, 2023 | msn.comTherapeuticsMD exploring strategic alternatives for companyNovember 14, 2023 | finance.yahoo.comTherapeuticsMD Announces Third Quarter 2023 Financial ResultsOctober 4, 2023 | bizjournals.comBoca Raton-based prescription service announces layoffs, says a third of workforce could be cutSeptember 20, 2023 | marketwatch.comTherapeuticsMD Inc. stock falls Wednesday, underperforms marketAugust 15, 2023 | marketwatch.comTherapeuticsMD Inc. stock outperforms market despite losses on the dayAugust 14, 2023 | finance.yahoo.comTherapeuticsMD Announces Second Quarter 2023 Financial ResultsAugust 9, 2023 | finance.yahoo.comMicron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of DirectorsJuly 5, 2023 | marketwatch.comTherapeuticsMD Inc. stock underperforms Wednesday when compared to competitorsJuly 4, 2023 | thestreet.comTherapeuticsMD Rejected by FDA, Delay Could Be FatalMay 23, 2023 | seekingalpha.comTherapeuticsMD: From Fallen And Forgotten To Cash CowMay 15, 2023 | finance.yahoo.comTherapeuticsMD Announces First Quarter 2023 Financial ResultsMay 10, 2023 | marketwatch.comTherapeuticsMD Inc. stock falls Tuesday, underperforms marketMay 10, 2023 | marketwatch.comTherapeuticsMD Inc. stock rises Wednesday, still underperforms marketMay 3, 2023 | marketwatch.comTherapeuticsMD Inc. stock falls Monday, underperforms marketApril 30, 2023 | marketwatch.comTherapeuticsMD Inc. stock underperforms Friday when compared to competitorsApril 23, 2023 | marketwatch.comTherapeuticsMD Inc. stock outperforms market on strong trading dayApril 14, 2023 | msn.comAll You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to BuySee More Headlines Receive TXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2023Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CUSIPN/A CIK25743 Webwww.therapeuticsmd.com Phone(561) 961-1900Fax561-431-3389Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,280,000.00 Net MarginsN/A Pretax Margin-594.62% Return on Equity-25.54% Return on Assets-14.87% Debt Debt-to-Equity RatioN/A Current Ratio1.72 Quick Ratio1.72 Sales & Book Value Annual Sales$1.30 million Price / Sales16.76 Cash FlowN/A Price / Cash FlowN/A Book Value$2.77 per share Price / Book0.68Miscellaneous Outstanding Shares11,530,000Free Float11,394,000Market Cap$21.79 million OptionableOptionable Beta1.03 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesGovernor Thomas G. Thompson (Age 82)Executive Chairman Comp: $150kMr. Marlan D. Walker J.D. (Age 48)Chief Executive Officer Comp: $1.13MMr. Robert G. Finizio (Age 53)Co-Founder Comp: $7.51kMr. Michael C. Donegan (Age 56)Interim CFO & Chief Accounting Officer Comp: $712.59kMs. Daniella Silva (Age 38)Chief Compliance Officer Mr. Benjamin Foulk (Age 54)Vice President of Human Resources Mr. Bharat Warrier (Age 46)Chief Manufacturing Officer Mr. Douglas SteelmanVice President of Market AccessMs. Dedra LydenVice President of Strategic Partnerships & InitiativesMore ExecutivesKey CompetitorsLisata TherapeuticsNASDAQ:LSTAMEI PharmaNASDAQ:MEIPSynlogicNASDAQ:SYBXIndaptus TherapeuticsNASDAQ:INDPOnconova TherapeuticsNASDAQ:ONTXView All CompetitorsInsiders & InstitutionsADAR1 Capital Management LLCBought 272,160 shares on 2/14/2024Ownership: 2.572%Marlan D WalkerSold 14,500 sharesTotal: $33,495.00 ($2.31/share)View All Insider TransactionsView All Institutional Transactions TXMD Stock Analysis - Frequently Asked Questions Should I buy or sell TherapeuticsMD stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares. View TXMD analyst ratings or view top-rated stocks. How have TXMD shares performed in 2024? TherapeuticsMD's stock was trading at $2.25 at the start of the year. Since then, TXMD stock has decreased by 17.3% and is now trading at $1.86. View the best growth stocks for 2024 here. When is TherapeuticsMD's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our TXMD earnings forecast. How were TherapeuticsMD's earnings last quarter? TherapeuticsMD, Inc. (NASDAQ:TXMD) announced its quarterly earnings results on Monday, August, 14th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by $0.17. The business had revenue of $0.44 million for the quarter. When did TherapeuticsMD's stock split? TherapeuticsMD's stock reverse split before market open on Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of TherapeuticsMD own? Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU). How do I buy shares of TherapeuticsMD? Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TXMD) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
